Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
Conditions: Prostate Adenocarcinoma Interventions: Drug: enzalutamide Sponsors: Alessa Therapeutics Inc.; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
Conditions: Lung Cancer; Lung Adenocarcinoma; Lung Squamous Cell Carcinoma; Non Small Cell Lung Cancer; Small-cell Lung Cancer Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials
Characteristics, Treatment Pattern and Outcomes for Patients With Surgically Resected Lung Cancers
Conditions: Lung Cancer; Lung Adenocarcinoma; Lung Squamous Cell Carcinoma; Non Small Cell Lung Cancer; Small-cell Lung Cancer Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials
PD-1 Inhibitor Plus Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer
Conditions: Pancreatic Adenocarcinoma Interventions: Drug: Gemcitabine, Nab-paclitaxel, Irinotecan; Radiation: Intensity-Modulated Radiation Therapy (IMRT); Drug: Camrelizumab Sponsors: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Conditions: Metastatic Esophageal Carcinoma; Advanced Unresectable Gastric Adenocarcinoma; Metastatic Gastric Cancer; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Esophageal Cancer; Metastatic Esophageal Adenocarcinoma; Metastatic Gastric Adenocarcinoma; Metastatic Gastric Carcinoma; Unresectable Esophageal Cancer; Unresectable Esophageal Adenocarcinoma; Unresectable Gastric Carcinoma; Unresectable Gastric Adenocarcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma Interventions: Biological: AgenT-797; Biological: Botensilimab; Drug: Balstilimab; Drug: Ramucirumab; Drug: Paclitaxel Sponsors: Me...
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction
Conditions: PD-1; Neoadjuvant Chemoradiotherapy; Gastroesophageal Junction Cancer Interventions: Drug: PD-1inhibitor Sponsors: Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
Effects of the Use of Probiotics on the Intestinal Microbiota of Patients With Gastric Cancer
Conditions: Gastric Adenocarcinoma; Gastric Cancer; Microbiome; Cytokines; Nutritional Status Interventions: Dietary Supplement: Formulation with probiotics; Other: Non-intervention for Clinical Outcomes -G5 Sponsors: Universidade Federal do Amazonas Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer
Conditions: Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma Interventions: Drug: SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection; Drug: Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection Sponsors: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
Peri-operative Zimberelimab (Anti-PD-1) vs Zimberelimab in Combination With Domvanalimab (Anti-TIGIT) in Resectable Mismatch Repair Deficient/Micro-satellite Unstable Gastric and Gastro-oesophageal Junctional Adenocarcinoma (ZODIAC)
Conditions: Metastatic Esophageal Cancer; Metastatic Gastric Cancer Interventions: Drug: Single agent zimberelimab; Drug: Combination zimberelimab + domvanalimab Sponsors: Royal Marsden NHS Foundation Trust; Gilead Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
Conditions: Metastatic Colorectal Cancer; Metastatic Gastroesophageal Adenocarcinoma; DPD Deficiency Interventions: Drug: Lonsurf; Drug: Oxaliplatin; Drug: Panitumumab; Drug: Bevacizumab; Drug: Trastuzumab; Drug: Nivolumab Sponsors: UNICANCER; Servier Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers
Conditions: Gastric Cancer; GastroEsophageal Cancer; Gastroesophageal Junction Adenocarcinoma Interventions: Other: MDASI-GI Sponsors: Memorial Sloan Kettering Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2024 Category: Research Source Type: clinical trials
Poorly Differentiated Adenocarcinoma of the Jejunum in a Patient With Peutz-Jeghers Syndrome: A Case Report
Conditions: Peutz-Jeghers Syndrome Sponsors: Haramaya Unversity Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction ，a Phase II Clinical Study
Conditions: Gastric Cancer; GastroEsophageal Cancer; Adenocarcinoma Interventions: Drug: Sintilimab,nab-paclitaxel and tegio Sponsors: Wu Jun Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials
First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC
Conditions: Advanced Gastric Adenocarcinoma Interventions: Drug: Apatinib Combined With Tislelizumab and Chemotherapy Sponsors: Renmin Hospital of Wuhan University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma
Conditions: Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Interventions: Drug: irinotecan; Drug: IBI343; Drug: paclitaxel Sponsors: Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials
